The Mesoblast Ltd (ASX: MSB) share price is in focus today after the company reported fourth-quarter net revenue of US$36 million, boosting full-year revenue to US$115 million for the period ended 30 June 2026.
Image source: Getty Images
What did Mesoblast report?
- Fourth quarter net revenue: US$36 million
- Full-year net revenue: US$115 million
- Ryoncil® uptake exceeded initial projections
- Strong capital position and funding for operations
What else do investors need to know?
Ryoncil® is the first mesenchymal stromal cell (MSC) product approved by the US FDA for any indication and remains the only FDA-approved option for children under 12 with steroid-refractory acute graft-versus-host disease (SR-aGvHD). This achievement has positioned Mesoblast as a leading developer of allogeneic cellular medicines targeting severe inflammatory diseases.
The company's manufacturing capabilities continue to deliver industrial-scale, off-the-shelf cellular medicines. Mesoblast also has an extensive intellectual property portfolio, with patents that provide commercial protection through to at least 2044 in key markets.
What's next for Mesoblast?
Looking ahead, Mesoblast expects continued revenue growth, supported by momentum across major US paediatric centres. The company's robust capital base and new five-year facility are intended to support further strategic initiatives, including label extensions and new blockbuster product launches.
Mesoblast is advancing its Ryoncil® therapy for additional inflammatory diseases, such as SR-aGvHD in adults and biologic-resistant inflammatory bowel disease, while its rexlemestrocel-L platform targets heart failure and chronic low back pain.
Mesoblast share price snapshot
Over the past 12 months, Mesoblast shares have risen 27%, outperforming the S&P/ASX 200 Index (ASX: XJO), which has risen 2% over the same period.
